1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Ciències Clíniques
  4. Articles publicats en revistes (Ciències Clíniques)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172406
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMontes Moreno, Santiago-
dc.contributor.authorBatlle, Ana-
dc.contributor.authorGonzález de Villambrosía, Sonia-
dc.contributor.authorSánchez-Espiridión, Beatriz-
dc.contributor.authorCereceda, Laura-
dc.contributor.authorGonzález Barca, Eva-
dc.contributor.authorPurroy, Noelia-
dc.contributor.authorPardal, Emilia-
dc.contributor.authorMartín, Alejandro-
dc.contributor.authorGrande, Carlos-
dc.contributor.authorMazorra, Francisco-
dc.contributor.authorInsunza, Andrés-
dc.contributor.authorQuero, Cristina-
dc.contributor.authorAguiar, David-
dc.contributor.authorCruz, Miguel Ángel-
dc.contributor.authorRueda Dominguez, Antonio-
dc.contributor.authorLlanos, Marta-
dc.contributor.authorGómez Codina, Jose-
dc.contributor.authorGarcía Arroyo, Francisco Ramón-
dc.contributor.authorCaballero, Dolores-
dc.contributor.authorConde, Eulogio-
dc.contributor.authorLópez, Andres-
dc.contributor.authorProvencio, Mariano-
dc.contributor.authorPiris, Miguel A.-
dc.date.accessioned2020-11-30T15:34:05Z-
dc.date.available2020-11-30T15:34:05Z-
dc.date.issued2014-08-01-
dc.identifier.issn0390-6078-
dc.identifier.urihttp://hdl.handle.net/2445/172406-
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.-
dc.format.extent4 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFerrata Storti Foundation-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3324/haematol.2014.104976-
dc.relation.ispartofHaematologica, 2014, vol. 99, num. 8, p. 138-141-
dc.relation.urihttps://doi.org/10.3324/haematol.2014.104976-
dc.rights(c) Ferrata Storti Foundation, 2014-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationQuimioteràpia-
dc.subject.classificationLimfomes-
dc.subject.classificationCèl·lules B-
dc.subject.classificationDiagnòstic-
dc.subject.classificationCèl·lules mare-
dc.subject.otherChemotherapy-
dc.subject.otherLymphomas-
dc.subject.otherB cells-
dc.subject.otherDiagnosis-
dc.subject.otherStem cells-
dc.titleRisk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec679858-
dc.date.updated2020-11-30T15:34:05Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid24763400-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
679858.pdf196.73 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.